[Federal Register Volume 72, Number 55 (Thursday, March 22, 2007)]
[Notices]
[Pages 13500-13501]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-5193]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Request for Nominations for Voting Members on Public Advisory 
Committees

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is requesting 
nominations for voting members to serve on the Allergenic Products 
Advisory Committee, Blood Products Advisory Committee, Cellular, Tissue 
and Gene Therapies Advisory Committee, Transmissible Spongiform 
Encephalopathies Advisory Committee, and the Vaccines and Related 
Biological Products Advisory Committee in the Center for Biologics 
Evaluation and Research (CBER). Nominations will be accepted for 
vacancies that will or may occur through January 31, 2008.
    FDA has a special interest in ensuring that women, minority groups, 
and individuals with disabilities are adequately represented on 
advisory committees, and therefore, encourages nominations of qualified 
candidates from these groups.

DATES: Because scheduled vacancies occur on various dates throughout 
each year, no cutoff date is established for the receipt of 
nominations. However, when possible, nominations should be received 6 
months before the date of scheduled vacancies for each year, as 
indicated in this notice.

ADDRESSES: All nominations and curricula vitae should be sent to the 
contact person listed in the FOR FURTHER INFORMATION CONTACT section of 
this document.

FOR FURTHER INFORMATION CONTACT: Donald Jehn, Division of Scientific 
Advisors and Consultants, Center for Biologics Evaluation and Research 
(HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, 
MD 20852-1448, 301-827-0314, e-mail: [email protected].

SUPPLEMENTARY INFORMATION: FDA is requesting nominations of voting 
members with appropriate expertise for vacancies listed below:

                                Table 1.
------------------------------------------------------------------------
   Advisory Committee and Expertise       No. of      Approximate Date
       Needed to Fill Vacancies         Vacancies    Members are Needed
------------------------------------------------------------------------
Allergenic Products Advisory                     2   As soon as possible
 Committee--allergy, immunology,
 pediatrics, internal medicine,
 biochemistry, statistics, and
 related scientific fields
                                                 2       August 31, 2007
------------------------------------------------------------------------
Blood Products Advisory Committee--              2    September 30, 2007
 clinical and administrative
 medicine, hematology, immunology,
 blood banking, surgery, internal
 medicine, biochemistry, engineering,
 statistics, biological and physical
 sciences, biotechnology, computer
 technology, epidemiology, consumer
 advocacy, sociology/ethics, clinical
 trials, behavioral science, risk
 communication and other related
 professions
------------------------------------------------------------------------

[[Page 13501]]

 
Cellular, Tissue, and Gene Therapies             1        March 31, 2007
 Advisory Committee--cellular
 therapies, tissue transplantation,
 gene transfer therapies and
 xenotransplantation including
 biostatistics, bioethics, hematology/
 oncology, human tissues and
 transplantation, reproductive
 medicine, general medicine and
 various medical specialties
 including surgery and oncology,
 immunology, virology, molecular
 biology, cell biology, developmental
 biology, tumor biology,
 biochemistry, rDNA technology,
 nuclear medicine, gene therapy,
 infectious diseases, and cellular
 kinetics
------------------------------------------------------------------------
Transmissible Spongiform                         4   As soon as possible
 Encephalopathies Advisory Committee--
 clinical and administrative
 medicine, hematology, virology,
 neurovirology, neurology, infectious
 diseases, immunology, transfusion
 medicine, surgery, internal
 medicine, biochemistry,
 biostatistics, epidemiology,
 biological and physical sciences,
 consumer advocacy, sociology/ethics,
 and other related professions
                                                 3      January 31, 2008
------------------------------------------------------------------------
Vaccines and Related Biological                  3   As soon as possible
 Products Advisory Committee--
 immunology, molecular biology, rDNA,
 virology, bacteriology,
 epidemiology, biostatistics,
 allergy, preventive medicine,
 infectious diseases, pediatrics,
 microbiology, biochemistry, and
 other related scientific fields
                                                 5      January 31, 2008
------------------------------------------------------------------------

I. Functions

A. Allergenic Products Advisory Committee

    The committee reviews and evaluates available data concerning the 
safety, effectiveness, and adequacy of labeling of marketed and 
investigational allergenic biological products or materials that are 
administered to humans for the diagnosis, prevention, or treatment of 
allergies and allergic diseases.

B. Blood Products Advisory Committee

    The committee reviews and evaluates available data concerning the 
safety, effectiveness, and appropriate use of blood and products 
derived from blood and serum or biotechnology which are intended for 
use in the diagnosis, prevention, or treatment of human diseases.

C. Cellular, Tissue and Gene Therapies Advisory Committee

    The committee reviews and evaluates available data relating to the 
safety, effectiveness, and appropriate use of human cells, human 
tissues, gene transfer therapies and xenotransplantation products which 
are intended for transplantation, implantation, infusion and transfer 
in the prevention and treatment of a broad spectrum of human diseases 
and in reconstruction, repair, or replacement of tissues for various 
conditions.

D. Transmissible Spongiform Encephalopathies Advisory Committee

    The committee reviews and evaluates available scientific data 
concerning the safety of products which may be at risk for transmission 
of spongiform encephalopathies having an impact on the public health.

E. Vaccines and Related Biological Products Advisory Committee

    The committee reviews and evaluates data concerning the safety, 
effectiveness, and appropriate use of vaccines and related biological 
products which are intended for use in the prevention, treatment, or 
diagnosis of human diseases.

II. Qualifications

    Persons nominated for membership on the committees shall have 
adequately diversified experience appropriate to the work of the 
committee in such fields as clinical and administrative medicine, 
engineering, biological and physical sciences, statistics, and other 
related professions. The nature of specialized training and experience 
necessary to qualify the nominee as an expert suitable for appointment 
may include experience in medical practice, teaching, and/or research 
relevant to the field of activity of the committee. The particular need 
for vacancies on each committee through January 31, 2008, is shown in 
Table 1 of this document. The term of office is up to 4 years, 
depending on the appointment date.

III. Nomination Procedures

    Any interested person may nominate one or more qualified persons 
for membership on one or more of the advisory committees. Self-
nominations are also accepted. Nominations shall include the name of 
the committee, a complete curriculum vitae of each nominee, current 
business address and telephone number, and shall state that the nominee 
is aware of the nomination, is willing to serve as a member (name of 
committee(s) must be specified), and appears to have no conflict of 
interest that would preclude membership. FDA will ask the potential 
candidates to provide detailed information concerning such matters as 
financial holdings, employment, and research grants and/or contracts to 
permit evaluation of possible sources of conflict of interest.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.

    Dated: March 14, 2007.
Randall W. Lutter,
Associate Commissioner for Policy.
[FR Doc. E7-5193 Filed 3-21-07; 8:45 am]
BILLING CODE 4160-01-S